Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals declining sales and financial performance, with a significant drop in LYNX product sales and overall revenue. Increased R&D expenses and cash burn raise concerns about financial health. Despite management's commitment to advancing clinical trials, regulatory risks and reliance on specialty distributors pose challenges. The Q&A session did not reveal any positive surprises. The negative sentiment is reinforced by the lack of new partnerships or optimistic guidance, leading to a predicted stock price movement in the negative range of -2% to -8%.
Key Financial Performance
Total Revenue $44.8 million in Q1 2026, includes product revenue net and royalties. Product revenue net was $42 million, a decline from $59.9 million in Q4 2025 and $43.1 million in Q1 2025. The decline was due to a $7.9 million inventory drawdown at specialty pharmacies and distributors.
Royalty Revenue $2.8 million in Q1 2026, compared to $15.6 million in Q4 2025 and $2.9 million in Q1 2025. The decline was attributed to a large shipment to a partner in China in Q4 2025.
NERLYNX Bottle Sales 2,328 bottles sold in Q1 2026, a 29% decrease quarter-over-quarter and flat year-over-year. Inventory decreased by 439 bottles in Q1 2026.
New Prescriptions (NRx) Increased by approximately 25% quarter-over-quarter and 11% year-over-year in Q1 2026.
Total Prescriptions (TRx) Decreased by approximately 4% quarter-over-quarter and 1% year-over-year in Q1 2026.
Gross Revenue from NERLYNX Sales $57.5 million in Q1 2026, compared to $82.9 million in Q4 2025.
Net Product Revenue from NERLYNX Sales $42 million in Q1 2026, a decrease from $59.9 million in Q4 2025 and $43.1 million in Q1 2025. U.S. net sales were $41.9 million in Q1 2026, compared to $55.2 million in Q4 2025.
Gross to Net Adjustment 27% in Q1 2026, slightly lower than 27.8% in Q4 2025, driven by lower government chargebacks.
Cost of Sales $10.4 million in Q1 2026, including $2.4 million for amortization of intangible assets, compared to $23.2 million in Q4 2025.
SG&A Expenses $18.4 million in Q1 2026, unchanged from Q4 2025.
R&D Expenses $19.8 million in Q1 2026, compared to $16.8 million in Q4 2025, driven by progress in clinical trials.
Net Loss (GAAP) $3.8 million or $0.07 per share in Q1 2026, compared to net income of $13.4 million or $0.27 per share in Q4 2025.
Non-GAAP Net Loss $1.9 million or $0.04 per share in Q1 2026.
Cash, Cash Equivalents, and Marketable Securities $101.5 million as of March 31, 2026, compared to $97.5 million at year-end 2025.
Cash Burn Approximately $4 million in Q1 2026, compared to $3.1 million in Q4 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Alisertib Phase II Trials: Interim data from ALISCA-Lung1 and ALISCA-Breast1 trials show promising results in small cell lung cancer and HER2-negative ER-positive breast cancer. Alisertib demonstrated better activity in biomarker-defined populations, particularly those with higher c-Myc activity. Dose escalation to 70 mg BID is planned for ALISCA-Lung1, and ALISCA-Lung2 will investigate alisertib in combination with paclitaxel. ALISCA-Breast1 will expand enrollment focusing on PIK3CA wild-type and ESR1 mutant patients.
NERLYNX Global Expansion: NERLYNX was launched in Thailand in Q1 2026, expanding its global reach in the extended adjuvant setting.
Revenue and Sales Performance: Total revenue for Q1 2026 was $44.8 million, with NERLYNX net product revenue at $42 million. U.S. net sales of NERLYNX were $41.8 million. Inventory drawdown impacted revenue by $7.9 million. New prescriptions increased by 25% quarter-over-quarter, while total prescriptions decreased by 4%.
Financial Guidance: Puma anticipates 2026 NERLYNX product revenue to range between $202 million and $206 million, with net income projected at $16 million to $19 million. The company is now debt-free after finalizing payments to Ethereum.
Focus on Biomarker-Driven Development: Puma is expanding its trials to focus on biomarker-specific populations, particularly in PIK3CA wild-type and ESR1 mutant patients for breast cancer and c-Myc activity in lung cancer. This aligns with their strategy to differentiate alisertib from other drugs.
In-Licensing and Acquisition: Puma is evaluating commercial and development-stage drugs for potential in-licensing or acquisition to diversify its portfolio and leverage existing infrastructure.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Total revenue for Q1 2026 was $44.8 million, a significant decline from $59.9 million in Q4 2025 and $43.1 million in Q1 2025. This includes a $7.9 million inventory drawdown, which could indicate challenges in demand or distribution.
Royalty Revenue Drop: Royalty revenue decreased to $2.8 million in Q1 2026 from $15.6 million in Q4 2025, primarily due to a large shipment to a partner in China in Q4 2025. This highlights dependency on specific large transactions.
Product Sales Decline: NERLYNX product sales dropped significantly, with 2,328 bottles sold in Q1 2026 compared to 3,298 bottles in Q4 2025, reflecting a 29% quarter-over-quarter decrease.
Clinical Trial Risks: Ongoing trials for alisertib in small cell lung cancer and HER2-negative ER-positive breast cancer face risks related to safety (e.g., neutropenia) and efficacy, with mixed results in progression-free survival (PFS) and response rates.
Regulatory and Approval Risks: The company is pursuing dose escalation and biomarker-focused trials, which may face regulatory hurdles and delays in achieving Phase III or approval milestones.
Increased R&D Expenses: R&D expenses are projected to increase by 34%-37% year-over-year in 2026, driven by clinical trial progress, which could strain financial resources.
Dependence on Specialty Distributors: 42% of NERLYNX sales rely on specialty distributors, with fluctuations in demand and inventory levels impacting revenue stability.
Economic and Market Uncertainty: The company acknowledges potential impacts from evolving trade policies and tariffs, though they currently do not foresee material effects.
Debt and Cash Flow Management: While the company is now debt-free, it reported a cash burn of $4 million in Q1 2026, which could challenge liquidity if revenue declines persist.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: Puma anticipates net NERLYNX product revenue for fiscal year 2026 to be in the range of $202 million to $206 million, higher than the prior guidance of $194 million to $198 million.
Q2 2026 Revenue Projections: NERLYNX product revenue is expected to be in the range of $50 million to $52 million. Royalties revenues are projected to be between $2 million and $3 million.
Net Income Guidance for 2026: Puma expects net income for the full year 2026 to be in the range of $16 million to $19 million, an increase from prior guidance of $10 million to $13 million.
Gross-to-Net Adjustment for 2026: The gross-to-net adjustment for the full year 2026 is expected to be between 26.5% and 27.5%, reflecting higher government chargebacks and Medicare/Medicaid share.
R&D and SG&A Expense Projections for 2026: R&D expenses are expected to increase by 34% to 37% year-over-year, driven by clinical trial progress. SG&A expenses are projected to increase by 1% to 2% year-over-year.
Clinical Trial Updates: Puma plans to expand enrollment in the ALISCA-Breast1 trial to focus on biomarker-specific cohorts, particularly patients who are PIK3CA wild-type, ESR1 mutant, or both. This expansion is anticipated in the second half of 2026. Additionally, the company aims to initiate the ALISCA-Lung2 trial in the second half of 2026, investigating alisertib in combination with paclitaxel.
Future Data Presentations: Puma anticipates presenting updated data from the ALISCA-Lung1 and ALISCA-Breast1 trials in the second half of 2026 or the first half of 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Given the emerging signal in c-Myc positive patients in both lung and breast cancers, how are you thinking about incorporating c-Myc biology into future trial designs? Will it evolve into a biomarker-enriched program with narrower patient selection?
A:Alan Auerbach explained that they are observing a stronger signal in c-Myc positive patients. In small cell lung cancer, a biomarker-focused approach might include various categories of c-Myc positivity. For ER-positive, HER2-negative breast cancer, the signal is enriched in ESR1 mutated and PIK3CA wild-type patients, particularly at the 50-milligram dose. This subset represents about 20% of the 40,000 patient population. The company benefits from existing biomarker testing in ER-positive breast cancer and plans to gather more data to refine their approach.
Q:Looking ahead to the next updates in both programs, what specific outcomes would give you confidence to advance or progress these programs to the next stage of development?
A:Alan Auerbach stated that they are fully committed to advancing both programs into Phase III. The focus will be on determining the design and exact patient population. They are looking for more patient numbers and longer duration data to guide their decisions.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. The management provided detailed and specific responses to all questions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ALISCA
ESR mutation
KM curve
Lung
NERLYNX
PFS month
PIKCA type
Slide KM
activity
alisertib
cancer
cell Myc
dose group
group ESR
milligram arm
milligram dose
milligram group
month PFS
month patient
mutation status
patient ESR
patient type
sale
score
slide patient
tissue
trial
tumor cell
type ESR
type ctDNA
PBYI Transcript
Puma Biotechnology, Inc. (PBYI) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call reveals declining sales and financial performance, with a significant drop in LYNX product sales and overall revenue. Increased R&D expenses and cash burn raise concerns about financial health. Despite management's commitment to advancing clinical trials, regulatory risks and reliance on specialty distributors pose challenges. The Q&A session did not reveal any positive surprises. The negative sentiment is reinforced by the lack of new partnerships or optimistic guidance, leading to a predicted stock price movement in the negative range of -2% to -8%.
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call highlighted a 5% YoY revenue increase and a shift from net loss to net income, indicating improved financial health. Operating expenses decreased by 10%, and cash flow turned positive, showcasing effective cost management. Despite uncertainties in forward-looking statements, the strong financial performance and optimistic guidance suggest a positive market reaction. The absence of negative insights from the Q&A section supports this sentiment.
Puma Biotechnology, Inc. (PBYI) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call reveals significant challenges, including a decline in total revenue and royalty revenue, competitive pressures, and regulatory risks. Although there is some positive news, like increased NERLYNX U.S. net sales, the overall sentiment is hindered by declining prescriptions, increased R&D costs, and financial pressures from debt obligations. The Q&A section indicates a cautious approach to spending and profitability, further reflecting concerns. These factors suggest a negative stock price movement over the next two weeks.
Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript
Positive8-7
Puma's earnings call summary highlights strong financial performance with increased revenue and net income, driven by higher NERLYNX sales. Although there are concerns about increasing R&D expenses and potential trial delays, the company maintains a positive outlook with optimistic guidance and strategic focus on expansion. The Q&A session reassures stakeholders with plans for fiscal responsibility and profitability. Despite some uncertainties, the overall sentiment is positive, suggesting a likely stock price increase.
PBYI Slides
PBYI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
